Review Article
Salvage Therapy of Multiple Myeloma: The New Generation Drugs
Table 3
New generation drugs in monotherapy or combined to novel agents.
| Drug | Association to novel agents | Phase | Dosage | | ORR | Reference |
| Carfilzomib | Monotherapy | 2 | 20–27 mg/m2 | 257 | 36 | [13] | Carfilzomib | In combination with lenalidomide and dexamethasone | 1/2 | 27 mg/m2 | 51 | 78 | [14] | Carfilzomib | In combination with pomalidomide | 1/2 | 27 mg/m2 | 82 | 70 | [15] | Ixazomib | Monotherapy | 1/2 | 2.97 mg/m2 | 32 | 26 | [16] | Pomalidomide | Monotherapy | 1/2 | 4 mg | 38 | 42 | [17] | Pomalidomide | In combination with high dose dexamethasone | 3 | 4 mg | 455 | 31 | [18] | Pomalidomide | In combination with cyclophosphamide and prednisone | 1/2 | 2.5 mg | 69 | 50 | [19] | Perifosine | In combination with bortezomib | 1/2 | 50 mg | 84 | 41 | [20] | Perifosine | In combination with lenalidomide | 1 | 50–100 mg | 32 | 73 | [21] | Vorinostat | In combination with bortezomib | 3 | 400 mg | 637 | 56.2 | [22] | Panobinostat | In combination with bortezomib | 1b | 20 mg | 47 | 52.9 | [23] | Panobinostat | In combination with bortezomib and dexamethasone | 2 | 20 mg | 55 | 34.5 | [24] |
|
|